Cargando…

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma

INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuta, Kyotaro, Izaki, Hirofumi, Shiozaki, Keito, Nakanishi, Ryoichi, Inai, Tohru, Kataoka, Hideyuki, Kudo, Eiji, Kanda, Kazuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413201/
https://www.ncbi.nlm.nih.gov/pubmed/34497992
http://dx.doi.org/10.1002/iju5.12334
_version_ 1783747611137671168
author Fukuta, Kyotaro
Izaki, Hirofumi
Shiozaki, Keito
Nakanishi, Ryoichi
Inai, Tohru
Kataoka, Hideyuki
Kudo, Eiji
Kanda, Kazuya
author_facet Fukuta, Kyotaro
Izaki, Hirofumi
Shiozaki, Keito
Nakanishi, Ryoichi
Inai, Tohru
Kataoka, Hideyuki
Kudo, Eiji
Kanda, Kazuya
author_sort Fukuta, Kyotaro
collection PubMed
description INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para‐aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed. CONCLUSION: Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma.
format Online
Article
Text
id pubmed-8413201
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84132012021-09-07 Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma Fukuta, Kyotaro Izaki, Hirofumi Shiozaki, Keito Nakanishi, Ryoichi Inai, Tohru Kataoka, Hideyuki Kudo, Eiji Kanda, Kazuya IJU Case Rep Case Reports INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para‐aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed. CONCLUSION: Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma. John Wiley and Sons Inc. 2021-06-24 /pmc/articles/PMC8413201/ /pubmed/34497992 http://dx.doi.org/10.1002/iju5.12334 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Fukuta, Kyotaro
Izaki, Hirofumi
Shiozaki, Keito
Nakanishi, Ryoichi
Inai, Tohru
Kataoka, Hideyuki
Kudo, Eiji
Kanda, Kazuya
Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title_full Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title_fullStr Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title_full_unstemmed Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title_short Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
title_sort complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413201/
https://www.ncbi.nlm.nih.gov/pubmed/34497992
http://dx.doi.org/10.1002/iju5.12334
work_keys_str_mv AT fukutakyotaro completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT izakihirofumi completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT shiozakikeito completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT nakanishiryoichi completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT inaitohru completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT kataokahideyuki completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT kudoeiji completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma
AT kandakazuya completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma